Cat. No. 1768
Chemical Name: (2E,4E,6E,8E)-Mono[(3R,4S,5S,6R)-5-
Biological ActivityAntibiotic and antiangiogenic agent; covalently binds and inhibits methionine aminopeptidase-2. Inhibits endothelial cell proliferation in vitro and tumor-induced angiogenesis in vivo. Also inhibits tumor growth in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Rodriguez-Nieto et al (2001) A re-evaluation of fumagillin selectivity towards endothelial cells. Anticancer Res. 21 3457. PMID: 11848509.
Lowther et al (1998) The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc.Natl.Acad.Sci.U.S.A. 95 12153. PMID: 9770455.
Ingber et al (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348 555. PMID: 1701033.
Jaronski (1972) Cytochemical evidence for RNA synthesis inhibition by fumagillin. J.Antibiot. 25 327. PMID: 4630977.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Fumagillin include:
Palmer et al (2012) A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. Br J Pharmacol 165 1891. PMID: 21943108.
Do you know of a great paper that uses Fumagillin from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Fumagillin, supplier, Methionine, aminopeptidase-2, inhibitors, inhibits, Proteases, Proteinases, antiangiogenics, angiogenesis, antibiotics, Tocris Bioscience, Aminopeptidase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailable
March 18 - 22, 2017
Little Rock, ARK, USA